INFINITY PHARMA
0416.616.681 · rovalta.com · 22/09/2026
INFINITY PHARMA
Overview
What does INFINITY PHARMA do?
INFINITY PHARMA is a Public limited company incorporated in 1976. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Nazareth-De Pinte. It employs on average 13,6 ETP workers (FTE).
9810 Nazareth-De Pinte · FlandreSee on map
Joint committees (2)
- 116
- 207
Trend over 19 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||||||||||||||||||||||
| Revenue | 10,7 M € | +0.6% | 10,7 M € | -6.2% | 11,4 M € | +58.3% | 7,2 M € | -29.8% | 10,2 M € | -34.7% | 15,7 M € | +47.7% | 10,6 M € | -4.1% | 11,1 M € | -7.2% | 11,9 M € | -7.7% | 12,9 M € | -4.7% | 13,6 M € | -17.6% | 16,5 M € | +3.8% | 15,9 M € | -14.2% | 18,5 M € | +13.5% | 16,3 M € | +7.8% | 15,1 M € | +1.1% | 14,9 M € | +2.1% | 14,6 M € | -4.4% | 15,3 M € |
| EBITDA | -97,1 k € | +67.9% | -302,8 k € | -199% | -101,2 k € | -41.7% | -71,4 k € | +85.5% | -491,9 k € | -122% | 2,3 M € | +23.4% | 1,8 M € | -1.7% | 1,9 M € | -25.6% | 2,5 M € | +40.4% | 1,8 M € | +14.0% | 1,6 M € | -43.3% | 2,8 M € | -1.0% | 2,8 M € | +5.3% | 2,6 M € | -42.9% | 4,6 M € | +6.8% | 4,3 M € | +15.2% | 3,8 M € | +6.8% | 3,5 M € | -2.0% | 3,6 M € |
| Operating result | -72,6 k € | +86.3% | -531 k € | -85.7% | -285,9 k € | -427% | -54,2 k € | +88.0% | -450,5 k € | -120% | 2,2 M € | +21.8% | 1,8 M € | -2.0% | 1,8 M € | -24.8% | 2,5 M € | +42.7% | 1,7 M € | +64.6% | 1 M € | -59.7% | 2,6 M € | +5.2% | 2,5 M € | +3.1% | 2,4 M € | -47.8% | 4,6 M € | +9.6% | 4,2 M € | +13.8% | 3,7 M € | +7.9% | 3,4 M € | -0.9% | 3,4 M € |
| Net result | -231,4 k € | +71.9% | -822,5 k € | +88.8% | -7,4 M € | -1364% | -503,4 k € | +92.2% | -6,4 M € | -123% | 28,4 M € | +113% | 13,3 M € | +3699% | 351 k € | +115% | -2,4 M € | -205% | 2,3 M € | -52.3% | 4,7 M € | +176% | 1,7 M € | +762% | -258,2 k € | -114% | 1,9 M € | -39.4% | 3,1 M € | -49.6% | 6,1 M € | +1056% | 527,4 k € | -44.6% | 951,6 k € | -17.2% | 1,1 M € |
| Balance sheet | |||||||||||||||||||||||||||||||||||||
| Equity | 16,4 M € | +29.8% | 12,6 M € | +914% | -1,6 M € | -127% | 5,8 M € | -81.4% | 31,3 M € | -17.0% | 37,7 M € | +303% | 9,4 M € | +209% | 3 M € | -54.9% | 6,7 M € | -96.6% | 194,8 M € | +1.2% | 192,6 M € | +247% | 55,5 M € | +2.1% | 54,3 M € | -2.3% | 55,6 M € | +3.5% | 53,7 M € | +0.3% | 53,5 M € | +0.6% | 53,2 M € | -1.6% | 54,1 M € | +360% | 11,8 M € |
| Total assets | 18,8 M € | +17.8% | 16 M € | -66.2% | 47,2 M € | -11.1% | 53,1 M € | -35.3% | 82 M € | -8.9% | 90,1 M € | +36.6% | 66 M € | +11.0% | 59,4 M € | -75.8% | 245,4 M € | -1.0% | 247,8 M € | +0.7% | 246 M € | -4.4% | 257,4 M € | -2.3% | 263,4 M € | +134% | 112,4 M € | +0.7% | 111,5 M € | -2.6% | 114,5 M € | +1.2% | 113,2 M € | +0.6% | 112,5 M € | +57.9% | 71,2 M € |
| Cash | 688,3 k € | +320% | 164 k € | -40.7% | 276,4 k € | +87.8% | 147,2 k € | -40.9% | 249,1 k € | +91.9% | 129,8 k € | -99.0% | 12,6 M € | +262% | 3,5 M € | -25.5% | 4,7 M € | +11.1% | 4,2 M € | +100% | 2,1 M € | -82.9% | 12,3 M € | +42.1% | 8,6 M € | +28.4% | 6,7 M € | +2058% | 311,4 k € | -89.2% | 2,9 M € | +9092% | 31,4 k € | -98.2% | 1,7 M € | -62.6% | 4,7 M € |
| Debts | 2,4 M € | -27.8% | 3,3 M € | -93.2% | 48,8 M € | +3.2% | 47,3 M € | -6.8% | 50,7 M € | -3.1% | 52,3 M € | -7.5% | 56,6 M € | +0.4% | 56,4 M € | -76.4% | 238,7 M € | +351% | 52,9 M € | -0.9% | 53,4 M € | -73.5% | 201,8 M € | -3.4% | 209 M € | +268% | 56,8 M € | -1.8% | 57,8 M € | -5.2% | 60,9 M € | +1.8% | 59,9 M € | +2.7% | 58,3 M € | -1.8% | 59,3 M € |
| Other | |||||||||||||||||||||||||||||||||||||
| Workforce | 13,6 ETP | -31.3% | 19,8 ETP | +3.7% | 19,1 ETP | +94.9% | 9,8 ETP | 0.0% | 9,8 ETP | +2.1% | 9,6 ETP | +2.1% | 9,4 ETP | +74.1% | 5,4 ETP | -6.9% | 5,8 ETP | -68.6% | 18,5 ETP | -11.9% | 21,0 ETP | -3.7% | 21,8 ETP | +2.3% | 21,3 ETP | -7.4% | 23,0 ETP | +2775% | 0,8 ETP | -94.2% | 13,9 ETP | -17.8% | 16,9 ETP | -14.2% | 19,7 ETP | -9.2% | 21,7 ETP |
Indicative valuation
As an indication, this company is worth
Board of directors
Seen on filing of 31/12/2025 · 4 active · 19 ended
Active mandates
Ended mandates
Other companies at this address
| Company | CBE no. |
|---|---|
| 0442.286.247 | |
FAGRON● Active | 0890.535.026 |
FAGRON BELGIUM● Active | 0403.767.052 |
FAGRON CAPITAL● Active | 0471.941.919 |
Financials
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Full model | Full model | Full model | Full model | Full model | Full model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 11/06/2026 | 15/09/2025 | 07/06/2024 | 05/06/2023 | 31/05/2022 | 25/05/2021 |
| General meeting | 12/05/2026 | 10/09/2025 | 14/05/2024 | 09/05/2023 | 10/05/2022 | 11/05/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Looking for more information about this company?
Try for 7 daysAnnual accounts filings
20 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Full model | 31/12/2025 | 12/05/2026 | 11/06/2026 | Dutch | |
| Full model | 31/12/2024 | 10/09/2025 | 15/09/2025 | Dutch | |
| Full model | 31/12/2023 | 14/05/2024 | 07/06/2024 | Dutch | |
| Full model | 31/12/2022 | 09/05/2023 | 05/06/2023 | Dutch | |
| Full model | 31/12/2021 | 10/05/2022 | 31/05/2022 | Dutch | |
| Full model | 31/12/2020 | 11/05/2021 | 25/05/2021 | Dutch | |
| Full model | 31/12/2019 | 12/05/2020 | 31/05/2020 | Dutch | |
| Full model | 31/12/2018 | 14/05/2019 | 23/05/2019 | Dutch | |
| Full model | 31/12/2017 | 08/05/2018 | 23/05/2018 | Dutch | |
| Full model | 31/12/2016 | 09/05/2017 | 09/05/2017 | Dutch | |
| Full model | 31/12/2015 | 30/06/2016 | 08/07/2016 | Dutch | |
| Full model | 31/12/2014 | 12/05/2015 | 05/06/2015 | Dutch | |
| Full model | 31/12/2013 | 13/05/2014 | 06/06/2014 | Dutch | |
| Full model | 31/12/2012 | 14/05/2013 | 24/05/2013 | Dutch | |
| Full model | 31/12/2011 | 08/05/2012 | 21/05/2012 | Dutch | |
| Full model | 31/12/2010 | 10/05/2011 | 26/05/2011 | Dutch | |
| Full model | 31/12/2009 | 11/05/2010 | 25/05/2010 | Dutch | |
| Full model | 31/12/2008 | 12/05/2009 | 27/05/2009 | French | |
| Full model | 31/12/2007 | 13/05/2008 | 06/06/2008 | French | |
| Full model | 31/12/2006 | 08/06/2007 | 20/09/2007 | French |
Valuation
Indicative valuation
As an indication, this company is worth
between 10 M€ and 25 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Seen on filing of 31/12/2025 · 4 active · 19 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
- Capital / shares02/01/2026KAPITAAL - AANDELEN
- Mandates31/12/2025ONTSLAGEN - BENOEMINGEN
- Capital / shares23/01/2025KAPITAAL - AANDELEN
- Mandates26/08/2024ONTSLAGEN - BENOEMINGEN
- Restructuring03/08/2023BENAMING - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
- Restructuring03/05/2023RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
- Mandates22/12/2022ONTSLAGEN - BENOEMINGEN - DIVERSEN
- Mandates22/12/2022ONTSLAGEN - BENOEMINGEN
Source: Belgian Official Gazette
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-231,4 k €↑
- 16/12/2025augmentation_capital
- 06/10/2025nominationLien Winne — commissaris
- 2024Annual accounts 2024-822,5 k €↑
- 20/12/2024augmentation_capital
- 20/12/2024reduction_capital
- 2023Annual accounts 2023-7,4 M €↓
- 09/05/2023reconductionPadilla Rafael — bestuurder
- 2023Name changePHARMA-PACK NV
- 2022Annual accounts 2022-503,4 k €↑
- 10/05/2022reconductionDe Jong Cornelia Neeltje — bestuurder
- 2021Annual accounts 2021-6,4 M €↓
- 12/05/2021nominationJohan Verlinden — bestuurder
- 12/05/2021nominationCéline Caveye — bestuurder
- 2021Name changeINFINITY PHARMA NV
- 2020Annual accounts 202028,4 M €↑
- 2019Annual accounts 201913,3 M €↑
- 2018Annual accounts 2018351 k €↑
- 2017Annual accounts 2017-2,4 M €↓
- 2015Annual accounts 20152,3 M €↓
- 2014Annual accounts 20144,7 M €↑
- 2013Annual accounts 20131,7 M €↑
- 2012Annual accounts 2012-258,2 k €↓
- 2011Annual accounts 20111,9 M €↓
- 2010Annual accounts 20103,1 M €↓
- 2009Annual accounts 20096,1 M €↑
- 2008Annual accounts 2008527,4 k €↓
- 2007Annual accounts 2007951,6 k €↓
- 2006Annual accounts 20061,1 M €
- 08/12/1976IncorporationPublic limited company